The AffloVest is battery-operated and uses Direct Dynamic Oscillation technology, which closely mimics hand CPT (Chest Physical Therapy) to help mobilise and clear secretions from the lungs, and allows for full freedom of mobility during treatment.
Doctors prescribe AffloVest for patients across a range of ages who have severe respiratory diseases such as bronchiectasis, cystic fibrosis, and certain neuromuscular diseases.
This next generation AffloVest, which began shipping September 1, is much lighter, quieter, and more efficient, with a smaller profile battery and long-life, state-of-the-art motors, offering improved patient ease of use.
The new AffloVest is on average 2 pounds lighter (more than 20% less weight) than the previous version, and uses streamlined components and tailored styling for a sleeker, slimmer fit.
International Biophysics brings to market medical devices and technologies aimed at improving treatment therapies and patient outcomes.
The company's precision ISO 13485 certified, FDA registered, quality controlled US manufacturing facility is located in Austin, Texas.
IDEAYA Biosciences enrols first patient in Phase 1 trial of PRMT5 inhibitor IDE892
Airiver Medical's Airiver Pulmonary DCB receives US FDA Breakthrough Device Designation
Novartis to build new radioligand therapy site in Texas
GSK to acquire 35Pharma for USD950m to strengthen cardiopulmonary pipeline
Epredia signs EU distribution deal with Mindpeak for AI pathology software
Gossamer Bio reports topline Phase 3 PROSERA results for seralutinib in PAH
CStone Pharmaceuticals' sugemalimab granted new indication by UK MHRA
Merck reports positive Phase 3 data for Enflonsia in high-risk children across two RSV seasons